All News
Holy Molly! TNFi (etanercept, adalimumab, infliximab, or golimumab) completely prevented stokes in patients with DADA2. #ACR19 @RheumNow
Jonathan Hausmann MD hausmannMD ( View Tweet)
#ACR19 @rheumnow ABS1513 Tofacitinib efficacy in PSA ⬇️ if BL BMI ≥ 35 . Safety consistent across all BL BMI categories. 3 CV events: non-fatal cerebrovascular accident, TIA(both Tofa 5 mg BID, BMI ≥ 30 – < 35), and artery revascularization in PBO; BMI ≥ 35 https://t.co/Y8htX6qETV
Olga Petryna DrPetryna ( View Tweet)
#ACR19 @rheumnow abs1913 Cohort study confirms the association of HLA-B*15 with peripheral joint involvement in AS but not in PSA, suggesting different mechanisms may be in play in the pathogenesis of peripheral joint and entheseal involvement between AS &PSA https://t.co/NdaHqI63oH
Olga Petryna DrPetryna ( View Tweet)
@AmandaOmbrello from @NIH_NIAMS at #ACR19 :
#Rheumatologists... Have you come across Adult-Onset Sporadic #PolyarteritisNodosa ?...
🚨 Don’t forget to check for ADA2 mutation!!! 🚨
@ACRheum @RheumNow https://t.co/1MP0wsD6Vr
Adam Kilian MD KilianMD ( View Tweet)
60%
The percentage of patients at @NIH's autoinflammatory disease cohort that are undifferentiated and do not have a specific disease diagnosis -Dr. Amanda Ombrello. #ACR19 @rheumnow https://t.co/d85OtnEA8o
Jonathan Hausmann MD hausmannMD ( View Tweet)
H2H Vedo vs Ada for gut disease (not joint)(no dose escalation in this trial)
#ACR19 @rheumnow 4M064 https://t.co/30JhLETdAK
Dr Irwin Lim _connectedcare ( View Tweet)
Panel on podcasting in rheumatology led by @RheumNow with @AdamJBrownMD @hausmannMD @EBRheum and myself. #ACR19 https://t.co/W1EMXe2qsd
Dr. Paul Sufka psufka ( View Tweet)
Shared & separate targets for autoimmune bowel disease & SpA. Nice summary
#ACR19 @rheumnow 4M064 https://t.co/5Mz7pM0hPv
Dr Irwin Lim _connectedcare ( View Tweet)
Treatment of patients with haploinsufficiency 20 (HA20) responds to HIGH (500mg!) doses of anakinra, TNF inhibitors, or--recently--JAK inhibitors. @AmandaOmbrello #ACR19 @RheumNow
Jonathan Hausmann MD hausmannMD ( View Tweet)
The questions that Dr. Amanda Ombrello (@NIH) asks when evaluating patients with recurrent fevers: -Age of onset -Frequency -Duration -Regularity -Height of fever -Prodromal symptoms #ACR19 @rheumnow
Jonathan Hausmann MD hausmannMD ( View Tweet)
Can lowering #uricacid improve hepatic fibrosis? Dr Naomi Schlesinger presented data from pegloticase #gout studies showing improvement/prevention of worsening vs pbo via the Fib-4 score Changes esp marked in pts with clinically important baseline Fib-4 score @RheumNow #ACR2019 https://t.co/8QUZvlcf57
Gout Study Group GoutGroup ( View Tweet)
PATCH: HCQ reduces congenital heart block (CHB) recurrence in babies born to Ro+ mothers w/ sibilings w/ CHB. This is encouraging data that further supports treatment induction in Ro+ pregnant pts to decrease fetal risk. https://t.co/0uU1zZP80l Plenary abs#1761 #ACR19 @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
“It’s so rare that a lupus clinical trial makes it to a plenary session...so cherish the moment!” -Dr Richard Furie on anifrolumab in SLE 🤣 #ACR19 @RheumNow
Maeve Gamble MaeveGamble ( View Tweet)
TULIP1 Anifrolumab RCT in SLE
Did NOT meet primary endpt SIR4 wk52 (36% v 40% PLBO, NS)
Post Hoc BICLA response DID favor Tx (46% v 30%, NNT~6)
Richard Furie: "Medication rules and endpoint selection are critical for SLE trials." Agreed.
#ACR19 Abst#1763 #ACRBest @RheumNow https://t.co/R4ily1Ubrz
Mike Putman EBRheum ( View Tweet)
Neonatal complete heart block is one to avoid. In Ro-pos mothers with a prev child with CHB, HCQ reduces rates from a historic 20% to 7.4% in the PATCH study. It seems we’re yet to fully realize the power of HCQ in conditions like these!
@nyuschoolofmed #ACR19 ABST1761 @RheumNow https://t.co/TMzmq6TjJx
David Liew drdavidliew ( View Tweet)
#ACR19 @Rheumnow ABS1217 pegadricase (0.2 mg/kg) +ImmTOR (0.15 mg/kg) selected for HtoH study of SEL-212 vs pegloticase based on Ph2T result showing addition of ImmTOR at ≥0.1 mg/kg ⬇️ ADA formation & 66% of pts maintained sUA levels < 6 mg/dL at Wk20.
Olga Petryna DrPetryna ( View Tweet)
Loving the aesthetics of the #ACR19 conference center this year. @RheumNow https://t.co/MOZgNDlfzw
Dr. Paul Sufka psufka ( View Tweet)
HOPE results: 6 week tapering treatment with po prednisolone in HOA pts improved VAS scores and US synovitis. Will this change the way you approach HOA? https://t.co/0MtW7esExU Plenary abs#1760 #ACR19 @RheumNow https://t.co/U5SStHuJoh
Dr. Rachel Tate uptoTate ( View Tweet)
Over the last 10 years racial and ethnic minorities are significantly underrepresented in rheumatoid arthritis clinical trials with no hope for improvement in the future. How applicable are these results when they do not reflect the population? #ACR19 abstract# 1160 https://t.co/WNSGfyCSKu
Dr. John Cush RheumNow ( View Tweet)
RheumNow's expanded coverage of the #ACR2019 annual meeting is sponsored in part by Horizon Therapeutics. All content chosen by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)